Systematic Review · e0001
Personalized microbiome biotherapeutics across recurrent CDI, cancer immunotherapy, ulcerative colitis and MDRO decolonization: a PRISMA 2020 systematic review with structured narrative synthesis
M.E. Shoranov, Sh.B. Tanabaeva, Z.S. Kachieva, A.M. Tlenchieva, A.Zh. Kauysbekov, Zh.S. Alibaeva. Personalized microbiome biotherapeutics across recurrent CDI, cancer immunotherapy, ulcerative colitis and MDRO decolonization: a PRISMA 2020 systematic review with structured narrative synthesis. Global Medical Reviews. 2026;1(1):e0001.
Abstract
Background
Microbiome biotherapeutics range from standardized indication-specific products to donor-, recipient- and ecology-informed interventions.
Objective
To evaluate the clinical efficacy, safety, and reproducibility of microbiome biotherapeutics and determine how donor, product, recipient, and longitudinal multi-omics characteristics have been used to personalize treatment.
Methods
PubMed/MEDLINE, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception to 8 July 2026, supplemented by regulatory sources, publisher searches, and citation tracking.
Results
Twenty-seven unique studies represented by 28 eligible reports were included across recurrent CDI, oncology and immunotherapy, ulcerative colitis, and MDRO decolonization.
Conclusions
Current routine evidence is strongest for standardized microbiota-based prevention of recurrent CDI after antibacterial therapy. Validated patient-level personalization is not yet established.